AU2012282936B2 - Process for the preparation of fluticasone propionate form 1 - Google Patents

Process for the preparation of fluticasone propionate form 1 Download PDF

Info

Publication number
AU2012282936B2
AU2012282936B2 AU2012282936A AU2012282936A AU2012282936B2 AU 2012282936 B2 AU2012282936 B2 AU 2012282936B2 AU 2012282936 A AU2012282936 A AU 2012282936A AU 2012282936 A AU2012282936 A AU 2012282936A AU 2012282936 B2 AU2012282936 B2 AU 2012282936B2
Authority
AU
Australia
Prior art keywords
fluticasone propionate
solvent
solution
process according
slurry
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012282936A
Other languages
English (en)
Other versions
AU2012282936A1 (en
Inventor
Eleftherios Kougoulos
Ivan MARZIANO
Martyn David TICEHURST
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of AU2012282936A1 publication Critical patent/AU2012282936A1/en
Application granted granted Critical
Publication of AU2012282936B2 publication Critical patent/AU2012282936B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2012282936A 2011-07-08 2012-07-06 Process for the preparation of fluticasone propionate form 1 Ceased AU2012282936B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161505612P 2011-07-08 2011-07-08
US61/505,612 2011-07-08
PCT/US2012/045660 WO2013009591A1 (en) 2011-07-08 2012-07-06 Process for the preparation of fluticasone propionate form 1

Publications (2)

Publication Number Publication Date
AU2012282936A1 AU2012282936A1 (en) 2014-01-16
AU2012282936B2 true AU2012282936B2 (en) 2016-11-10

Family

ID=47506422

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012282936A Ceased AU2012282936B2 (en) 2011-07-08 2012-07-06 Process for the preparation of fluticasone propionate form 1

Country Status (10)

Country Link
US (2) US10370402B2 (enExample)
EP (1) EP2729480A4 (enExample)
JP (2) JP2014520848A (enExample)
KR (3) KR20200117056A (enExample)
CN (2) CN103649104A (enExample)
AU (1) AU2012282936B2 (enExample)
CA (1) CA2840401C (enExample)
MX (2) MX376564B (enExample)
WO (1) WO2013009591A1 (enExample)
ZA (1) ZA201309531B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2729480A4 (en) * 2011-07-08 2014-12-31 Pfizer Ltd PROCESS FOR THE PREPARATION OF FLUTICASONE PROPIONATE, FORM 1
PL3517541T3 (pl) 2012-05-08 2020-12-28 Nicox Ophthalmics, Inc. Postać polimorficzna propionianu flutykazonu
WO2015118474A1 (en) * 2014-02-07 2015-08-13 Mylan Laboratories Ltd. Process for the purification of fluticasone propionate using a ketone solvent and water as anti-solvent
CN111662353A (zh) * 2019-03-05 2020-09-15 上海谷森医药有限公司 一种糠酸氟替卡松晶型1的制备方法
BR112021020319A2 (pt) * 2019-04-10 2021-12-14 Eupraxia Pharmaceuticals Inc Processo para fabricar cristais de fármaco de distribuição de tamanho e morfologia desejadas
CN110759960B (zh) * 2019-10-30 2021-03-23 山东赛托生物科技股份有限公司 一种丙酸氟替卡松的精制方法
CN115103591B (zh) * 2019-12-27 2026-06-19 度勒科特公司 结晶性和液体结晶性25-羟基-胆甾-5-烯-3-硫酸钠及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038811A1 (en) * 1998-12-24 2000-07-06 Glaxo Group Limited Apparatus and process for preparing crystalline particles
WO2003061816A1 (en) * 2002-01-22 2003-07-31 Glaxo Group Limited Apparatus and process for preparing crystalline particles
US20030181432A1 (en) * 2000-06-29 2003-09-25 Lancaster Robert William Process for preparing and harvesting crystalline particles

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2088877B (en) 1980-02-15 1984-07-04 Glaxo Group Ltd Androstane 17 carbothioates
GB9001635D0 (en) * 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
SE9501384D0 (sv) * 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
GB9622173D0 (en) * 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
GB9925934D0 (en) * 1999-11-03 1999-12-29 Glaxo Group Ltd Novel apparatus and process
GB0125604D0 (en) * 2001-10-25 2001-12-19 Glaxo Group Ltd Novel process
GB0202564D0 (en) * 2002-02-04 2002-03-20 Glaxo Group Ltd Process
US7208613B2 (en) * 2002-06-20 2007-04-24 Sun Pharmaceutical Industries Limited Synthesis of s-fluoromethyl 6α,9α-difluoro-11β-hydroxy-16α-methyl-17α-propionyloxy-3-oxoandrosta-1,4-diene-17β-carbothioate
GB0315509D0 (en) 2003-07-02 2003-08-06 Meridica Ltd Dispensing device
US7314516B2 (en) * 2004-12-29 2008-01-01 Five Star Technologies, Inc. Hydrodynamic cavitation crystallization device and process
EP2729480A4 (en) * 2011-07-08 2014-12-31 Pfizer Ltd PROCESS FOR THE PREPARATION OF FLUTICASONE PROPIONATE, FORM 1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038811A1 (en) * 1998-12-24 2000-07-06 Glaxo Group Limited Apparatus and process for preparing crystalline particles
US20030181432A1 (en) * 2000-06-29 2003-09-25 Lancaster Robert William Process for preparing and harvesting crystalline particles
WO2003061816A1 (en) * 2002-01-22 2003-07-31 Glaxo Group Limited Apparatus and process for preparing crystalline particles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STECKEL, H. ET. AL. International Journal of Pharmaceutics, 2003, 258, 63-75 *

Also Published As

Publication number Publication date
US10370402B2 (en) 2019-08-06
EP2729480A1 (en) 2014-05-14
KR20140048237A (ko) 2014-04-23
EP2729480A4 (en) 2014-12-31
CA2840401A1 (en) 2013-01-17
CN103649104A (zh) 2014-03-19
CA2840401C (en) 2016-05-17
KR20190107165A (ko) 2019-09-18
CN106977575A (zh) 2017-07-25
US20200024298A1 (en) 2020-01-23
WO2013009591A1 (en) 2013-01-17
JP2017031161A (ja) 2017-02-09
KR20200117056A (ko) 2020-10-13
AU2012282936A1 (en) 2014-01-16
MX2014000192A (es) 2014-04-25
JP2014520848A (ja) 2014-08-25
MX376564B (es) 2025-03-07
ZA201309531B (en) 2014-08-27
KR102163368B1 (ko) 2020-10-08
MX2020011330A (es) 2020-11-24
US20140141247A1 (en) 2014-05-22

Similar Documents

Publication Publication Date Title
US20200024298A1 (en) Process for the preparation of fluticasone propionate form i
JP4331619B2 (ja) 臭化チオトロピウムの結晶性微粒子
CN117263848A (zh) 一种雷芬那辛的吸入喷雾剂
AU2018303293B2 (en) Amorphous form of vilanterol trifenatate and processes for the preparation thereof
EA011157B1 (ru) Способ получения кристаллического циклесонида, обладающего определенным размером частиц
CN103804366B (zh) 一种拉呋替丁晶型化合物
AU2017278484B2 (en) Crystalline pharmaceutical co-crystals of glycopyrronium bromide with lactose
US20100120737A1 (en) Amorphous ciclesonide
CN113912656A (zh) N-乙酰基-d-氨基葡萄糖的晶型及其制备方法、应用
JP5265876B2 (ja) アンドラストの新規で安定な結晶構造体
CN115894440B (zh) 奥布替尼化合物的晶型及其制备方法
CN110396101A (zh) 曲索芬头孢曲松钠药物制剂治疗细菌性内膜炎的新适应症
CN119970731A (zh) 一种含有沙美特罗和噻托铵盐组合物的吸入干粉制剂及其制备方法
CN119925617A (zh) 一种用于治疗慢性阻塞性肺病(copd)的药物组合物及其制备方法
CN119925363A (zh) 一种治疗copd的药物组合物及其制备方法
EP2022796A1 (en) Amorphous ciclesonide
EP3405173A1 (en) Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
CN104649968B (zh) 一种孟鲁司特钠倍半水合物化合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired